Altered in vitro uptake of the radiolabelled antiviral imaging "probe" E-5-(2-125iodovinyl)-2'-deoxyuridine following administration of acyclovir.
Current developments in the use of radiolabelled antiviral drugs as specific "probes" for virus-infected cells in vivo may allow the specific neuroradiological diagnosis of herpes encephalitis. As "blind therapy" with the antiviral drug acyclovir may precede specific neuroradiological diagnosis, the aim of the present study was to investigate whether or not acyclovir interferes with the uptake of the radioprobe E-5-(2-125Iodovinyl)-2'-deoxyuridine (rIVDU) by virus-infected cells in vitro. Acyclovir treatment (0.1 to 10 micrograms/ml) was shown to increase initial radioprobe uptake by virus-infected cells. However, with continued incubation in the presence of acyclovir, intracellular radioactivity decreased to a level not significantly different from that associated with noninfected cells. A mechanism to explain these results is proposed. It was concluded that concurrent acyclovir therapy could interfere with neuroradiological diagnosis using rIVDU, although this may not occur with all the candidate radioprobes currently under investigation.
Klapper
P E
PE
Department of Medical Microbiology, Medical School, University of Manchester, England.
Lewis
A G
AG
Cleator
G M
GM
Templeton
P
P
Longson
M
M
D000212:Acyclovir / Q000009:adverse effects / Q000494:pharmacology*; D000818:Animals; D000998:Antiviral Agents / Q000493:pharmacokinetics*; D002460:Cell Line; D004347:Drug Interactions; D007065:Idoxuridine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D007457:Iodine Radioisotopes; D018139:Simplexvirus / Q000187:drug effects
D000998:Antiviral Agents; D007457:Iodine Radioisotopes; C030360:5-(2-iodovinyl)-2'-deoxyuridine; D007065:Idoxuridine; D000212:Acyclovir